Core Insights - JD Health released its 2024 Environmental, Social, and Governance (ESG) report, showcasing its sustainable development practices in the healthcare sector, emphasizing safety, efficiency, convenience, and warmth in health consumption experiences [1] Compliance and Governance - In 2024, JD Health established a comprehensive compliance system with a focus on user health, implementing a "three-line defense" and "five dimensions" approach to ensure compliance across all operations, including drug management and internet hospital services [3] - The company achieved ISO13485 certification for medical devices, expanding its compliance certifications to cover all business areas, including drug management and internet hospitals [3] - JD Health published standardized treatment paths for 43 diseases and established 4 core medical quality management systems, totaling 265 standardized treatment paths and 16 core systems over two years, enhancing the quality management of online medical services [3] Service Innovation - JD Health innovated its healthcare service model to meet diverse user needs, achieving an average of over 490,000 online consultations per day by the end of 2024 [4] - The company created a closed-loop service model integrating "doctor consultations," "home tests," "home delivery of medications," and "home nursing," allowing patients to access comprehensive healthcare services from home [4] - JD Health expanded its "JD Home Fast Testing" services to 12 cities, offering 149 home testing products, and launched nearly 40 home nursing projects through the "JD Nurse at Home" service [4] Technological Empowerment - JD Health accelerated the application of large model technology across various service scenarios, aiming to provide a seamless online and offline healthcare experience [7] - The company introduced several intelligent health services, including "KangKang" health assistant and "ChatGPT-like" AI psychological companion, enhancing the efficiency and accuracy of healthcare services [7] - JD Health's "Smart Doctor Assistant" became the most widely used intelligent diagnostic tool among doctors, improving clinical decision-making and patient management [7] Social Responsibility - JD Health deepened its corporate social responsibility initiatives, aiding 637 patients through its rare disease care program, with a total value of assistance reaching 6.24 million yuan [8] - The "Medical Heart Station" project, in collaboration with top medical institutions, provided support to over 23,000 patients, improving the healthcare experience for rare disease patients [8] - The company conducted 22 donation activities in 2024, donating over 1.53 million health items to rural communities and disaster relief efforts [10] - JD Health launched a "Expired Medicine Recycling" initiative, successfully collecting and professionally disposing of 11 tons of expired medications, engaging 57,000 users across 315 cities [10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [5][3]. Core Insights - The company reported a revenue of 58.2 billion (+8.6%) for the full year 2024, with a notable increase in service revenue by 18.9% to 9.4 billion, reflecting a strategic focus on expanding market share [1]. - Non-IFRS net profit reached 4.79 billion (+15.9%), with a significant increase in attributable net profit by 94.3% to 4.16 billion, showcasing strong profitability growth [1][3]. - The company is leveraging AI technology and digital tools to enhance operational efficiency, resulting in a reduction of administrative costs by 1.3 percentage points [2]. Financial Summary - The company achieved a gross profit of 13.3 billion (+12.2%) with a gross margin of 22.9% (+0.7 percentage points) in 2024 [1]. - The projected revenues for 2025, 2026, and 2027 are 66.9 billion, 76.1 billion, and 86.5 billion respectively, with attributable net profits expected to be 3.59 billion, 4.13 billion, and 4.79 billion [3][4]. - The earnings per share (EPS) are forecasted to be 1.12, 1.29, and 1.50 yuan for the years 2025, 2026, and 2027 respectively [3][4]. User Growth and Market Position - The company has expanded its active user base to 184 million (+6.6%), with an average revenue per user (ARPU) of 317 yuan (+2.0%) [1]. - Daily online consultations have exceeded 490,000 (+8.9%), indicating a strong demand for its services [2]. - The integration of AI in healthcare services is expected to open new commercial pathways, particularly in B2B services, under the supportive policy environment for "AI + healthcare" [2].